Motor and non-motor symptoms in Parkinson’s disease (PD) lead to progressive disability. Current therapies often failed to halt this disease progression. This underscores the promise of phytotherapeutic approaches. Aloysia citriodora, traditionally used in Paraguay for its sedative and anxiolytic properties, has shown antioxidant and anti-inflammatory activity in preclinical studies, suggesting its potential for neuroprotection. This study aimed to assess the effect of A. citriodora extract (EAc) in a reserpine (RES)-induced model of PD. Male mice received 20 s.c. injections of 0.1 mg/kg RES or vehicle, every other day, alongside daily oral administration of EAc (30, 150, or 300 mg/kg). Catalepsy test was performed every other day, and assessment of vacuous chewing movements (VOM) every 10 d. To investigate non-motor symptoms, short-term memory was assessed using the novel object recognition (NOR) test. Our results show that, even at low doses, EAc attenuates catalepsy progression. Interestingly, a reduction in VOM was observed (by d 30) with 30 mg/Kg of EAc, while all doses produced comparable effects at d 40. In addition, 150 mg/kg of EAc prevented cognitive impairment in NOR. Taken together, our results suggest that EAc shows a neuroprotective effect, attenuating catalepsy, orofacial dyskinesia, and cognitive impairments induced by RES. This study highlights the potential use of A. citriodora as a promising therapy for the prevention and/or treatment of PD.